The double-blind, placebo-controlled, ascending, single and multiple, oral dose study is designed to provide preliminary information on the safety, tolerability and pharmacokinetics of PSN602 in healthy lean and obese subjects, as well as on the effects of PSN602 on appetite and food intake in healthy obese subjects.
Anker Lundemose, president of Osi, said: “Our research efforts are focused on designing innovative, next-generation, small molecule compounds to provide safer or more effective options for the treatment of type 2 diabetes and obesity.”